Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

23.54 +0.94 (+4.16%)

Streaming Delayed Price Updated: 11:16 AM EDT, Jun 24, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	406,769
Open	22.67
Bid (Size)	23.54 (1,300)
Ask (Size)	23.57 (500)
Prev. Close	22.60
Today's Range	22.67 - 23.61
52wk Range	19.69 - 28.35
Shares Outstanding	162,625,379
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth ↗

May 19, 2026

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide...

Via MarketBeat

ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms ↗

May 12, 2026

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders,...

Via MarketBeat

Performance

YTD	-10.5%	-10.5%
1 Month	+10.7%	+10.7%
3 Month	+12.3%	+12.3%
6 Month	-15.4%	-15.4%
1 Year	+4.7%	+4.7%

More News

Acadia (ACAD) Q1 2026 Earnings Transcript ↗

May 06, 2026

Via The Motley Fool

Acadia Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings Miss Sends Stock Lower ↗

May 06, 2026

Via Chartmill

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Surpasses $1 Billion Revenue Milestone in 2025, Beats Q4 EPS Estimates ↗

February 25, 2026

Via Chartmill

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

May 06, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career

April 30, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

April 28, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting

April 17, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

April 15, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal

April 07, 2026

Via MarketMinute

Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit

April 07, 2026

Via Finterra

Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

April 07, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar

April 06, 2026

Via MarketMinute

Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

March 12, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

March 03, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗

March 03, 2026

Via The Motley Fool

Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome

March 02, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗

March 02, 2026

Via The Motley Fool

Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗

March 02, 2026

Via The Motley Fool

Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts ↗

February 27, 2026

Via Stocktwits

ACADIA (ACAD) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Via The Motley Fool

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview

February 25, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

February 23, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗

February 23, 2026

Via The Motley Fool

Frequently Asked Questions

Is ACADIA Pharmaceuticals Inc. - Common Stock publicly traded?

Yes, ACADIA Pharmaceuticals Inc. - Common Stock is publicly traded.

What exchange does ACADIA Pharmaceuticals Inc. - Common Stock trade on?

ACADIA Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock?

The ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock is ACAD on the Nasdaq Stock Market

What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?

The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 23.54

When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?

The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 06/24/26 11:16 AM ET

What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?

The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 3.83B

How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?

ACADIA Pharmaceuticals Inc. - Common Stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.